/
MGTX
$12.54+$0.43 (+3.55%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$1.1B
93M shares
52-week range
$6.31 – $12.57
100% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2.96
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $13.3M | $15.6M | $37.7M | $15.9M | $14.0M | $33.3M | $81.4M |
| Cost of revenue | $2.1M | $0 | $0 | $0 | $0 | $0 | $23.8M | $4.8M |
| Gross profit | −$2.1M | $13.3M | $15.6M | $37.7M | $15.9M | $14.0M | $9.5M | $76.5M |
| Gross margin | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 28.5% | 94.0% |
| R&D | $33.6M | $24.9M | $33.9M | $66.7M | $85.7M | $103.8M | $119.5M | $129.6M |
| Operating income | −$78.1M | −$58.3M | −$62.6M | −$72.8M | −$116.4M | −$137.1M | −$164.2M | −$106.0M |
| EBITDA | −$78.1M | −$52.5M | −$53.7M | −$71.4M | −$116.1M | −$57.1M | −$121.7M | −$89.4M |
| Net income | −$82.9M | −$54.7M | −$58.0M | −$79.6M | −$129.6M | −$84.0M | −$147.8M | −$114.2M |
| Net margin | — | -411.9% | -372.6% | -211.0% | -814.2% | -599.5% | -444.1% | -140.3% |
| EPS (diluted) | -4.37 | -1.58 | -1.43 | -1.80 | -2.87 | -1.49 | -2.12 | -1.42 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $50M | $-1.61 | $-2.31–$-0.54 | 6 |
| 2027 | $97M | $-1.54 | $-2.31–$0.62 | 6 |
| 2028 | $100M | $-1.75 | $-2.15–$-1.30 | 3 |
| 2029 | $266M | $-0.56 | $-1.92–$0.13 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
MeiraGTx Holdings plc Ordinary Shares
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.
www.meiragtx.com- Employees
- 409
- IPO / List date
- Jun 8, 2018
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds MGTX.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in MGTX as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded MGTX yet.
